Synthesis of hapten, generation of specific polyclonal antibody and development of ELISA with high sensitivity for therapeutic monitoring of crizotinib

Crizotinib (CZT) is a potent drug used for treatment of non-small cell lung cancer (NSCLC); however, its circulating concentration variability has been associated with acquired resistance and toxicity, restricting the success of cancer treatment. As such, the development of an assay that monitors CZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shehri, Mona M., El-Azab, Adel S., El-Gendy, Manal A., Hamidaddin, Mohammed A., Darwish, Ibrahim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370279/
https://www.ncbi.nlm.nih.gov/pubmed/30742664
http://dx.doi.org/10.1371/journal.pone.0212048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370279/
https://www.ncbi.nlm.nih.gov/pubmed/30742664
http://dx.doi.org/10.1371/journal.pone.0212048

Ejemplares similares